Furthermore, KLF6 is upregulated during liver fibrosis, which was confirmed in an animal model of liver cirrhosis and human liver cirrhosis (Bureau et al., 2008; Vatakuti et al., 2015), and targeted KLF6 therapy has been demonstrated to inhibit advanced liver fibrosis and attenuates angioarchitectural changes that typify cirrhosis (Thabut et al., 2011). The gene discussed is KLF6; the disease is cirrhosis of liver.